Risk for respiratory complications in patients with type 2 diabetes not increased with use of GLP1 receptor agonists.

Prenatal opioid exposure not linked to a clinically meaningful increase in risk for neuropsychiatric disorders.

Despite patient beliefs, no impact seen on severity, duration of cough.

Findings seen for neurodevelopmental outcomes at 6 years of age or older.

Adjusted odds ratios of 1.70, 1.40, and 1.30 seen for proton pump inhibitors, H2 receptor antagonists, and generic antacids, respectively.

CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4 and vascular endothelial growth factor A.

Compared with dupilumab, a significantly higher proportion of patients treated with upadacitinib achieved both EASI 90 and a Worst Pruritus Numerical Rating Scale of 0 or 1.

Findings show efficacy and cost-effectiveness among adults aged 50 years and older following training session.

The approval was based on data from three phase 3 trials which compared the efficacy of different dosing regimens of pivmecillinam to placebo, to another oral antibacterial drug, and to ibuprofen.

A phase 3, open-label study (MEND-PNPO) evaluating MC-1 in patients with confirmed PNPO deficiency (via genetic analysis) is currently in the works.